News related to Rescriptor (Delavirdine) and/or conditions it is approved for
First days after HIV infection may hold vaccine key (Reuters)
Source: Y! Health HIV & AIDS News [2008.12.01]
Reuters - The body's initial response to contracting HIV could provide the answers scientists need to develop a vaccine for the AIDS-causing virus, a Nobel-winning expert said on Monday.
Herpes Suppression May Not Prevent HIV Infection
Source: MedicineNet Genital Herpes In Women Specialty [2008.06.20]
Title: Herpes Suppression May Not Prevent HIV Infection
Category: Health News
Created: 6/20/2008 2:00:00 AM
Last Editorial Review: 6/20/2008
Newly Reported HIV Cases On The Rise In Europe
Source: Health News from Medical News Today [2008.12.01]
The HIV epidemic remains of major public health importance in Europe, with evidence of increasing transmission of HIV in several countries. Case reporting data from 2007 shows that the number of newly reported cases in Europe continues to rise. Between 2000 and 2007, the rate of HIV infection has almost doubled, from 40 per million population to 76/million.
GPs In For The Long Haul For Our Hiv/ Aids Patients - Royal Australian College Of General Practitioners
Source: HIV / AIDS News From Medical News Today [2008.12.01]
On World AIDS Day, The Royal Australian College of General Practitioners (RACGP) is reaffirming the central role played by general practitioners in HIV prevention, and in providing care and support for people living with HIV infection. The college is also taking this opportunity to highlight new challenges as the epidemic changes in Australia.
Keeping The Promise To Face HIV Globally And Locally - Wisconsin
Source: HIV / AIDS News From Medical News Today [2008.11.29]
December 1st marks the 20th anniversary of World AIDS Day, and state health officials encourage everyone to learn more about the global AIDS/HIV epidemic and personal risk for HIV infection. "World AIDS Day reminds us that we are all part of a larger, worldwide AIDS/HIV epidemic," said Secretary Karen Timberlake.
Long-Term TITAN Study Evaluates PREZISTA(R)/ritonavir Vs. Lopinavir/ritonavir As Part Of HIV Combination Therapy In Treatment-Experienced Adults
Source: Conferences News From Medical News Today [2008.11.19]
Tibotec recently announced long-term study results from a phase 3 clinical trial, which compared PREZISTA(R) (darunavir)/ritonavir to lopinavir/ritonavir, as part of HIV combination therapy, in lopinavir/r-naive, treatment-experienced HIV-1 infected adults. A 96-week resistance analysis from the study, known as TITAN, was presented in an oral presentation at the Ninth International Congress on Drug Therapy in HIV Infection (HIV9) in Glasgow, UK on November 13, 2008.
Case Of Patient "Cured" Of HIV Baffles Doctors
Source: Lymphoma / Leukemia News From Medical News Today [2008.11.14]
Doctors and experts are baffled by the case of a 42-year old male American patient living in Berlin whose 10-year long HIV infection appears to have been "cured" by a bone marrow transplant given to treat his acute myeloid leukemia.
|
